company background image
ACST

Acasti PharmaTSXV:ACST Stock Report

Last Price

CA$1.52

Market Cap

CA$67.3m

7D

-10.1%

1Y

-79.3%

Updated

26 Jan, 2022

Data

Company Financials +
ACST fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

ACST Stock Overview

Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases.

Acasti Pharma Competitors

Johnson & Johnson

NYSE:JNJ

US$441.3b

Pfizer

NYSE:PFE

US$294.9b

AbbVie

NYSE:ABBV

US$235.3b

Eli Lilly

NYSE:LLY

US$217.1b

Price History & Performance

Summary of all time highs, changes and price drops for Acasti Pharma
Historical stock prices
Current Share PriceCA$1.52
52 Week HighCA$12.40
52 Week LowCA$1.33
Beta1.42
1 Month Change-19.15%
3 Month Change-26.21%
1 Year Change-79.35%
3 Year Change-86.13%
5 Year Change-88.55%
Change since IPO-97.03%

Recent News & Updates

Shareholder Returns

ACSTCA PharmaceuticalsCA Market
7D-10.1%-9.7%-2.9%
1Y-79.3%-57.7%16.1%

Return vs Industry: ACST underperformed the Canadian Pharmaceuticals industry which returned -57.8% over the past year.

Return vs Market: ACST underperformed the Canadian Market which returned 15% over the past year.

Price Volatility

Is ACST's price volatile compared to industry and market?
ACST volatility
ACST Average Weekly Movement14.3%
Pharmaceuticals Industry Average Movement11.6%
Market Average Movement9.8%
10% most volatile stocks in CA Market17.3%
10% least volatile stocks in CA Market3.7%

Stable Share Price: ACST is more volatile than 75% of Canadian stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: ACST's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Canadian stocks.

About the Company

FoundedEmployeesCEOWebsite
200232Jan D'Alvisehttps://www.acastipharma.com

Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre, an omega-3 phospholipid therapeutic to treat patients with hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada.

Acasti Pharma Fundamentals Summary

How do Acasti Pharma's earnings and revenue compare to its market cap?
ACST fundamental statistics
Market CapUS$53.30m
Earnings (TTM)-US$11.00m
Revenue (TTM)US$196.00k

272.3x

P/S Ratio

-4.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ACST income statement (TTM)
RevenueUS$196.00k
Cost of RevenueUS$76.00k
Gross ProfitUS$120.00k
ExpensesUS$11.12m
Earnings-US$11.00m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.25
Gross Margin61.22%
Net Profit Margin-5,613.78%
Debt/Equity Ratio0%

How did ACST perform over the long term?

See historical performance and comparison

Valuation

Is Acasti Pharma undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ACST (CA$1.52) is trading below our estimate of fair value (CA$48.53)

Significantly Below Fair Value: ACST is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ACST is unprofitable, so we can't compare its PE Ratio to the Canadian Pharmaceuticals industry average.

PE vs Market: ACST is unprofitable, so we can't compare its PE Ratio to the Canadian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ACST's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ACST is good value based on its PB Ratio (0.5x) compared to the CA Pharmaceuticals industry average (1.6x).


Future Growth

How is Acasti Pharma forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

22.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ACST is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ACST is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ACST is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ACST is forecast to have no revenue next year.

High Growth Revenue: ACST is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ACST's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Acasti Pharma performed over the past 5 years?

-3.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ACST is currently unprofitable.

Growing Profit Margin: ACST is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ACST is unprofitable, and losses have increased over the past 5 years at a rate of 3.6% per year.

Accelerating Growth: Unable to compare ACST's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ACST is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (30.8%).


Return on Equity

High ROE: ACST has a negative Return on Equity (-9.63%), as it is currently unprofitable.


Financial Health

How is Acasti Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: ACST's short term assets ($54.5M) exceed its short term liabilities ($4.5M).

Long Term Liabilities: ACST's short term assets ($54.5M) exceed its long term liabilities ($1.1M).


Debt to Equity History and Analysis

Debt Level: ACST is debt free.

Reducing Debt: ACST had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ACST has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if ACST has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Acasti Pharma current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ACST's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ACST's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ACST's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ACST's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ACST's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average management tenure


CEO

Jan D'Alvise (66 yo)

5.58yrs

Tenure

US$428,040

Compensation

Ms. Janelle D’Alvise, also known as Jan, has been an Independent Director of Spectral Medical Inc. since June 03, 2021. She is the Chairman of the board of The ObG Project. She has been the Chief Executive...


CEO Compensation Analysis

Compensation vs Market: Jan's total compensation ($USD428.04K) is above average for companies of similar size in the Canadian market ($USD158.71K).

Compensation vs Earnings: Jan's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: ACST's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Members

Experienced Board: ACST's board of directors are considered experienced (4.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 265.7%.


Top Shareholders

Company Information

Acasti Pharma Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Acasti Pharma Inc.
  • Ticker: ACST
  • Exchange: TSXV
  • Founded: 2002
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: CA$67.318m
  • Shares outstanding: 44.29m
  • Website: https://www.acastipharma.com

Number of Employees


Location

  • Acasti Pharma Inc.
  • 3009 boulevard de la Concorde East
  • Suite 102
  • Laval
  • Quebec
  • H7E 2B5
  • Canada

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/26 01:05
End of Day Share Price2022/01/25 00:00
Earnings2021/09/30
Annual Earnings2021/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.